Trosunilimab

Phase 2Monoclonal antibody

AbbVie

Trosunilimab is one of 51 small molecule programs targeting Crohn's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseRecruiting

Crohn's DiseasePhase 2

Recruiting

Competition

Competitive Landscape

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

28 2

Humira

Novartis

Approved

22 3

Entyvio

Takeda

Approved

13 4

Omvoh

Eli Lilly

Approved

8 5

Trexall

Jazz Pharmaceuticals

Approved

1 6

Opzelura

Calciferol

Levulan

Sun Pharmaceutical Industries, Inc.

Lamprene

Rocaltrol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Crohn's Disease

NCT06548542

Q4 2031

Phase 2Recruiting

Crohn's Disease

NCT07697456

Clinical

Trials by Indication[1]

Crohn's Disease2 trials

A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07697456·2,000 enrolled

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06548542·540 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Trosunilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trosunilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trosunilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Trosunilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q4 2031

Trials by Indication[1]

Crohn's Disease2 trials

References

Drug Info

Quick Facts

Related News